Bibliografía
1. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol. 1997; 28:1221-1225.
2. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11:155-168.
3. Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999; 79:1347-1355.
4. Baker EA, Stephenson TJ, Reed MW, et al. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 2002; 55:300-304.
5. Bijker N, Rutgers EJ, Peterse JL, et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol. 2001; 27:135-140.
6. Black MM, Zachrau RE, Hankey BF, et al. Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology? Cancer. 1996; 78:778-788.
7. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000; 6:4823-4830.
8. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998; 161:6845-6852.
9. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004; 64:1675-1686.
10. Dixon AR, Ellis IO, Elston CW, et al. A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991; 63:634-635.
11. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997; 88:801-810.
12. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000; 2:252-257.
13. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2:161-174.
14. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94:1546-1554.
15. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000; 486:247-251.
16. Fingleton B, Vargo-Gogola T, Crawford HC, et al. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 2001; 3:459-468.
17. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312:665-673.
18. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16:441-452.
19. Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994; 269:16766-16773.
20. Gonzalez L, Corte MD, Vazquez J, et al. Study of matrix metalloproteinases and their tissular inhibitors in ductal “in situ” carcinomas of the breast. Histophatology. 2008; in press
21. Gonzalez LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007; 97:957-963.
22. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat. 2004; 88:197-204.
23. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003; 362:95-102.
24. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002; 21:2245-2252.
25. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999; 189:161-168.
26. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355:528-533.
27. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3:537-549.
28. Kim HJ, Park CI, Park BW, et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J. 2006; 47:333-342.
29. Knauper V, Cowell S, Smith B, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997; 272:7608-7616.
30. Knauper V, Lopez-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996; 271:1544-1550.
31. Lebeau A, Nerlich AG, Sauer U, et al. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res. 1999; 19:4257-4264.
32. Li HC, Cao DC, Liu Y, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004; 88:75-85.
33. Manes S, Llorente M, Lacalle RA, et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 1999; 274:6935-6945.
34. McCarthy K, Maguire T, McGreal G, et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999; 84:44-48.
35. Mimori K, Ueo H, Shirasaka C, et al. Clinical significance of MT1-MMP mRNA expression in breast cancer. Oncol Rep. 2001; 8:401-403.
36. Nakopoulou L, Giannopoulou I, Stefanaki K, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol. 2002; 197:307-313.
37. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18:1135-1149.
38. Nielsen BS, Rank F, Lopez JM, et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 2001; 61:7091-7100.
39. Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001; 114:111-118.
40. Nofech-Mozes S, Spayne J, Rakovitch E, et al. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol. 2005; 12:256-264.
41. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002; 117:723-728.
42. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004; 10:7621-7628.
43. Polette M, Clavel C, Cockett M, et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis. 1993; 13:31-37.
44. Ree AH, Florenes VA, Berg JP, et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997; 3:1623-1628.
45. Remacle A, McCarthy K, Noel A, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer. 2000; 89:118-121.
46. Rifkin DB, Mazzieri R, Munger JS, et al. Proteolytic control of growth factor availability. Apmis. 1999; 107:80-85.
47. Schrohl AS, Christensen IJ, Pedersen AN, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics. 2003; 2:164-172.
48. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004; 10:2289-2298.
49. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995; 345:1154-1157.
50. Sivula A, Talvensaari-Mattila A, Lundin J, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005; 89:215-220.
51. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516.
52. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103:1237-1241.
53. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995; 270:5331-5338.
54. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, et al. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 2001; 65:55-61.
55. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003; 89:1270-1275.
56. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases)--on the main stage of cancer? Cancer Cell. 2004; 5:409-410.
57. Visscher DW, Hoyhtya M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer. 1994; 59:339-344.
58. Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007; 96:903-911.
59. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett. 2006; 236:292-301.
60. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000; 14:163-176.
|